UnknownPhase 2

Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy

South Korea39 participantsStarted 2021-11-01

Plain-language summary

This study aims to investigate the efficacy and safety of bromfenac sodium hydrate eye drops in patients with familial exudative vitreoretinopathy receiving diode laser photocoagulation.

Who can participate

Age range1 Month – 7 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Newly diagnosed patients with familial exudative vitreoretinopathy * Needing diode laser photocoagulation * Consent to the study Exclusion Criteria: * History of corneal diseases * History of hypersensitivity to bromfenac sodium * History of hypersensitivity to non-steroidal anti-inflammatory drugs * Progressive ocular infection * Liver diseases * Hypersensitivity to sulfur dioxide * Receiving anti-coagulation drugs * History of coagulopathies

What they're measuring

Macular edema response rate

Timeframe: 4 weeks after the diode laser photocoagulation

Trial details

NCT IDNCT05107921

SponsorSeoul National University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-20

Contact for this trial

Jeong Hun Kim, MD, PhD

82-2-2072-3446 steph25@snu.ac.kr

View on ClinicalTrials.gov More Familial Exudative Vitreoretinopathies trials